Expression of Inflammasomes in HCV Patients Before and After Treatment
试验速览
- 阶段
- 4 期
- 入组人数
- 50
- 主要终点
- changes in the exprssion level of inflammasomes
研究概览
简要总结
Hepatitis C virus has been identified a quarter of a decade ago as a leading cause of chronic viral hepatitis that can lead to cirrhosis and hepatocellular carcinoma. Only a minority of patients can clear the virus spontaneously during acute infection. Elimination of HCV during acute infection correlates with a rapid induction of innate and a delayed induction of adaptive immune responses. The majority of patients is unable to clear the virus and develops viral persistence despite the ongoing innate and adaptive immune response. The virus usually develops several strategies to escape these immune responses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Chronic hepatitis C virus patients.
- •Patients do not start treatment protocol.
排除标准
- •Pregnant women.
- •Hepato-cellular carcinoma patients.
- •Autoimmune disease patients.
- •Patients with liver cirrhosis.
- •Patients who refuse to participate in the study
结局指标
主要结局
changes in the exprssion level of inflammasomes
时间窗: 6 monthes
observe the changes in the exprssion level of inflammasomes in the selected chronic HCV patients before treatment with Sofosbuvir 400 mg and Daclatasvir 60 mg daily for 12 weeks and after sustained virological response at 12 weeks following the end of treatment (SVR12).
次要结局
未报告次要终点
研究者
Aya Fergany
princible inverstigator
Assiut University